Surgical Trauma-induced CCL2 Upregulation Mediates Lung Cancer Progression by Promoting Treg Recruitment in Mice and Patients

Zheng, Xiaoyu; Zhu, Xidong; Ning, Jinfeng; Zhu, Kaibin; Yan, Yubo; Zhang, Jian; Bu, Jianlong; Liu, Mengfeng; Xu, Shidong

doi:10.1080/07357907.2021.1977314

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the increase of regulatory T cell levels in liver metastatic cancer tissues inhibited the infiltration of immune cells into the tumor tissue, which promoted the growth and metastasis of tumor cells, and ultimately led to the poor prognosis of patients. The role of regulatory T cells has also been confirmed in the studies of other malignant tumors, further supporting the findings of the present study (15)(16)(17)(18)(19)(20).…”

Section: Discussionsupporting

confidence: 91%

Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis

Wang¹,

Tang²,

Ouyang³

et al. 2023

J Gastrointest Oncol

View full text Add to dashboard Cite

Background: Liver metastasis is common in colorectal cancer patients. Immunotherapy covers a wide range of tumor types and is safer than traditional radiotherapy and chemotherapy. However, its overall effective rate is only 20-40%. At present, there is a lack of relevant research clarifying whether the changes and clinical significance of the immune microenvironment in colorectal cancer patients with liver metastasis are conducive to enhancing the promotion and further improving the efficacy of immunotherapy. Methods:We retrospectively collected the data of 50 colorectal cancer patients with liver metastasis treated in Chongqing University Cancer Hospital from January 2017 to January 2019. Liver metastatic cancer tissues and normal liver tissues were collected to detect the levels of immune cells in the two samples. At the same time, the correlation between T-cell subsets in the liver metastatic cancer tissue immune microenvironments of colorectal cancer patients and prognosis was analyzed.Results: Compared with the normal liver tissues, the level of T helper cell 1/T helper cell 2 (Th1/Th2) in the liver metastatic cancer tissues was significantly decreased (0.88±0.24 vs. 1.34±0.27, P=0.000), while the levels of regulatory T cells were markedly increased (8.57±2.31 vs. 6.89±1.71, P=0.000). The Th1/Th2 level in liver metastatic cancer tissue exhibited a good predictive value for recurrence and survival 3 years after surgery, and the areas under the curves were 0.783 (95% confidence interval: 0.649-0.916, P=0.002) and 0.763 (95% confidence interval: 0.628-0.898, P=0.001), respectively. Moreover, the regulatory T-cell level in liver metastatic cancer tissue had a good predictive value for recurrence and survival at 3 years postoperatively, and the areas under the curves were 0.788 (95% confidence interval: 0.656-0.919, P=0.002) and 0.763 (95% confidence interval: 0.628-0.897, P=0.001), respectively. Conclusions:The immunosuppressive condition of liver metastasis in colorectal cancer patients was related to poor prognosis.

show abstract

Section: Discussionsupporting

confidence: 91%

Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis

Wang¹,

Tang²,

Ouyang³

et al. 2023

J Gastrointest Oncol

View full text Add to dashboard Cite

show abstract

“…Zhao et al have shown that the surgical trauma contributes to promote excessive Treg recruitment by upregulating C-C motif chemokine ligand 2 (CCL2) expression. They indicated that CCL2 markedly promoted the percentage and migration of Tregs, whereas anti-CCL2 antibodies significantly inhibited the percentage and migration of Tregs (88). Nevertheless, far-too-little attention has been paid on the related signaling pathway and the molecular mechanism by which CCL2 promotes Treg recruitment.…”

Section: Surgical Traumamentioning

confidence: 99%

T lymphocyte cell: A pivotal player in lung cancer

Yuan

Wang

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Lung cancer is responsible for the leading cause of cancer-related death worldwide, which lacks effective therapies. In recent years, accumulating evidence on the understanding of the antitumor activity of the immune system has demonstrated that immunotherapy is one of the powerful alternatives in lung cancer therapy. T cells are the core of cellular immunotherapy, which are critical for tumorigenesis and the treatment of lung cancer. Based on the different expressions of surface molecules and functional points, T cells can be subdivided into regulatory T cells, T helper cells, cytotoxic T lymphocytes, and other unconventional T cells, including γδ T cells, nature killer T cells and mucosal-associated invariant T cells. Advances in our understanding of T cells’ functional mechanism will lead to a number of clinical trials on the discovery and development of new treatment strategies. Thus, we summarize the biological functions and regulations of T cells on tumorigenesis, progression, metastasis, and prognosis in lung cancer. Furthermore, we discuss the current advancements of technologies and potentials of T-cell-oriented therapeutic targets for lung cancer.

show abstract

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi,

Li,

Niu

et al. 2024

Sig Transduct Target Ther

View full text Add to dashboard Cite

Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles in both normal physiology and the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. In this review, we summarized the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, we highlighted the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborated on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discussed the challenges and opportunities this presents for therapeutic intervention. We also examined the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, we evaluated the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Besides, we also focused on the ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.

show abstract

Surgical Trauma-induced CCL2 Upregulation Mediates Lung Cancer Progression by Promoting Treg Recruitment in Mice and Patients

Cited by 4 publications

References 37 publications

Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis

Clinical significance and changes to the immune microenvironment of colorectal cancer patients with liver metastasis

T lymphocyte cell: A pivotal player in lung cancer

Targeting cytokine and chemokine signaling pathways for cancer therapy

Contact Info

Product

Resources

About